|
Mutation Information
|
Mutation Site
|
I50V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
33252379
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Chinese medical journal |
|
Title
|
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. |
|
Author
|
Su B,Yao C,Zhao QX,Cai WP,Wang M,Lu HZ,Chen YY,Liu L,Wang H,He Y,Zheng YH,Li LH,Chen JF,Yu JH,Zhu B,Zhao M,Sun YT,Lun WH,Xia W,Sun LJ,Dai LL,Jiang TY,Wang MX,Zheng QS,Peng HY,Wang Y,Lu RJ,Hu JH,Xing H,Shao YM,Xie D,Zhang T,Zhang FJ,Wu H,TALENT Study Team. |
|
Evidence
|
One patient in the NRTI group developed both major (I50V and V82A) and minor protease resistance mutations (L33F, Q58E, and L10F).
|
|
|
HIV Mutation Detail Information